These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38173030)

  • 21. PPP1R81 correlates with the survival and cell proliferation in lower-grade glioma.
    Xiao F; Jie X; Zhou X; Guo Y; Sun GF; Lin L; Hu GW; Huang K; Guo H
    Biosci Rep; 2023 May; 43(5):. PubMed ID: 37083601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated RECQL1 expression predicts poor prognosis and associates with tumor immune infiltration in low-grade glioma.
    Wang G; Cen Y; Wang C; Xiang W; Li S; Ming Y; Chen L; Zhou J
    Transl Cancer Res; 2022 Jun; 11(6):1552-1564. PubMed ID: 35836526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TUBA1C is a Prognostic Marker in Low-grade Glioma and Correlates with Immune Cell Infiltration in the Tumor Microenvironment.
    Zhu H; Hu X; Gu L; Jian Z; Li L; Hu S; Qiu S; Xiong X
    Front Genet; 2021; 12():759953. PubMed ID: 34721547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics.
    Lin WW; Ou GY; Zhao WJ
    J Cell Mol Med; 2021 Nov; 25(21):10111-10125. PubMed ID: 34597473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrated analysis of inflammatory response subtype-related signature to predict clinical outcomes, immune status and drug targets in lower-grade glioma.
    Cao Y; Zhu H; Chen Q; Huang H; Xie D; Li X; Jiang X; Ren C; Peng J
    Front Pharmacol; 2022; 13():914667. PubMed ID: 36091778
    [No Abstract]   [Full Text] [Related]  

  • 26. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas.
    Li Y; Feng Y; Luo F; Peng G; Li Y
    Front Immunol; 2022; 13():1089792. PubMed ID: 36726969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CCNB2 is a novel prognostic factor and a potential therapeutic target in low-grade glioma.
    Wang D; Sun H; Li X; Wang G; Yan G; Ren H; Hou B
    Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34908101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significance of NotchScore and JAG1 in predicting prognosis and immune response of low-grade glioma.
    Shi B; Ge F; Cai L; Yang Y; Guo X; Wu R; Fan Z; Cao B; Wang N; Si Y; Lin X; Dong W; Sun H
    Front Immunol; 2023; 14():1247288. PubMed ID: 38022677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An N6-methyladenosine regulation- and mRNAsi-related prognostic index reveals the distinct immune microenvironment and immunotherapy responses in lower-grade glioma.
    Tang G; Peng J; Huo L; Yin W
    BMC Bioinformatics; 2023 Jun; 24(1):225. PubMed ID: 37264314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
    Hao YP; Wang WY; Qiao Q; Li G
    Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High expression of ZFP36L2 correlates with the prognosis and immune infiltration in lower-grade glioma.
    Zhou M; Li J; Chen C
    Front Genet; 2022; 13():914219. PubMed ID: 35910229
    [No Abstract]   [Full Text] [Related]  

  • 32. MAGOH is correlated with poor prognosis and is essential for cell proliferation in lower-grade glioma.
    Xiao F; Long Z; Guo Y; Zhu H; Zhang Z; Xiao Y; Hu G; Yang Q; Huang K; Guo H
    Aging (Albany NY); 2023 Jun; 15(12):5713-5733. PubMed ID: 37390121
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Zhu Q; Liu Z; Cheng X; Liang W; Wang H; Li P; Zhang J; Chen Y; Gao Y; Qian R
    Heliyon; 2023 Jul; 9(7):e18185. PubMed ID: 37519705
    [No Abstract]   [Full Text] [Related]  

  • 34. CLSPN is a potential biomarker associated with poor prognosis in low-grade gliomas based on a multi-database analysis.
    Jia Y; Cheng X; Liang W; Lin S; Li P; Yan Z; Zhang M; Ma W; Hu C; Wang B; Liu Z
    Curr Res Transl Med; 2022 Sep; 70(4):103345. PubMed ID: 35487167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of VASH1 as a Potential Prognostic Biomarker of Lower-Grade Glioma by Quantitative Proteomics and Experimental Verification.
    Aili Y; Maimaitiming N; Maimaiti A; Liu W; Qin H; Ji W; Mahemuti Y; Wang Y; Wang Z
    J Oncol; 2022; 2022():2621969. PubMed ID: 36504559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
    Xu S; Tang L; Liu Z; Luo C; Cheng Q
    Front Immunol; 2021; 12():731048. PubMed ID: 34659218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring the prognostic potential of m6A methylation regulators in low-grade glioma: implications for tumor microenvironment modulation.
    Wu H; Chen S; Hu Z; Ge R; Ma L; You C; Huang Y
    Eur J Med Res; 2024 Jan; 29(1):19. PubMed ID: 38173044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DUSP10 is a novel immune-related biomarker connected with survival and cellular proliferation in lower-grade glioma.
    Xiao F; Zhu H; Guo Y; Zhang Z; Sun G; Huang K; Guo H; Hu G
    Aging (Albany NY); 2023 Jun; 15(12):5673-5697. PubMed ID: 37387540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Transcriptional Signature of PDGF-DD Activated Natural Killer Cells Predicts More Favorable Prognosis in Low-Grade Glioma.
    Sun Y; Sedgwick AJ; Palarasah Y; Mangiola S; Barrow AD
    Front Immunol; 2021; 12():668391. PubMed ID: 34539622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Novel 10-Gene Signature Predicts Poor Prognosis in Low Grade Glioma.
    Liu W; Zou J; Ren R; Liu J; Zhang G; Wang M
    Technol Cancer Res Treat; 2021; 20():1533033821992084. PubMed ID: 33550903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.